-
EP2078080
European procedure
Extract from the Register of European Patents
EP About this file: EP2078080
| EP2078080 - CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 22.04.2016 Database last updated on 13.07.2024 | Most recent event Tooltip | 01.09.2017 | Lapse of the patent in a contracting state New state(s): CY | published on 04.10.2017 [2017/40] | Applicant(s) | For all designated states Coley Pharmaceutical GmbH Merowingerplatz 1a 40225 Düsseldorf / DE | [2009/29] | Inventor(s) | 01 /
DEBELAK, Harald Richard-Wagner-Str. 41 40724 Hilden / DE | 02 /
UHLMANN, Eugen Zum Talbik 31 61479 Glashuetten / DE | 03 /
JURK, Marion Klosterstr. 4 41540 Dormagen / DE | [2009/29] | Representative(s) | Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2012/33] |
| Former [2009/29] | Ricol, David Gerard, et al Pfizer Limited European Patent Department Ramsgate Road Sandwich, Kent CT13 9NJ / GB | Application number, filing date | 07870434.3 | 27.09.2007 | [2012/05] | WO2007IB04389 | Priority number, date | US20060847811P | 27.09.2006 Original published format: US 847811 P | [2009/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2008068638 | Date: | 12.06.2008 | Language: | EN | [2008/24] | Type: | A2 Application without search report | No.: | EP2078080 | Date: | 15.07.2009 | Language: | EN | The application published by WIPO in one of the EPO official languages on 12.06.2008 takes the place of the publication of the European patent application. | [2009/29] | Type: | B1 Patent specification | No.: | EP2078080 | Date: | 17.06.2015 | Language: | EN | [2015/25] | Search report(s) | International search report - published on: | EP | 13.11.2008 | Classification | IPC: | C12N15/11, A61K31/7125, C07H21/00, A61P37/04 | [2009/29] | CPC: |
C12N15/117 (EP,NO,US);
C07H21/00 (EP,KR,NO,US);
C12N15/11 (KR);
A61K31/7125 (KR);
A61P11/00 (EP);
A61P11/06 (EP);
A61P31/12 (EP);
A61P31/14 (EP);
A61P31/16 (EP);
A61P31/18 (EP);
A61P31/20 (EP);
A61P31/22 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/04 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
C12N2310/17 (EP,US);
C12N2310/31 (US);
C12N2310/315 (US);
C12N2310/33 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2015/25] |
| Former [2009/29] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR | Extension states | HR | Not yet paid | Title | German: | CPG-OLIGONUKLEOTID-ANALOGE MIT HYDROPHOBEN T-ANALOGEN MIT VERSTÄRKTER IMMUNSTIMULATORISCHER AKTIVITÄT | [2009/29] | English: | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | [2009/29] | French: | ANALOGUES OLIGONUCLÉOTIDIQUES DE CPG CONTENANT DES ANALOGUES T HYDROPHOBES AYANT UNE ACTIVITÉ IMMUNOSTIMULANTE AMÉLIORÉE | [2009/29] | Entry into regional phase | 27.04.2009 | National basic fee paid | 13.05.2009 | Designation fee(s) paid | 13.05.2009 | Examination fee paid | Examination procedure | 19.03.2009 | Amendment by applicant (claims and/or description) | 13.05.2009 | Examination requested [2009/29] | 15.07.2009 | Despatch of a communication from the examining division (Time limit: M06) | 01.03.2010 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 15.04.2010 | Reply to a communication from the examining division | 10.01.2012 | Despatch of a communication from the examining division (Time limit: M06) | 26.06.2012 | Reply to a communication from the examining division | 08.09.2014 | Despatch of a communication from the examining division (Time limit: M02) | 30.10.2014 | Reply to a communication from the examining division | 30.01.2015 | Communication of intention to grant the patent | 05.05.2015 | Receipt of the translation of the claim(s) | 06.05.2015 | Fee for grant paid | 06.05.2015 | Fee for publishing/printing paid | Divisional application(s) | EP15172158.6 / EP2960332 | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 15.07.2009 | Opposition(s) | 18.03.2016 | No opposition filed within time limit [2016/21] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 15.04.2010 | Request for further processing filed | 15.04.2010 | Full payment received (date of receipt of payment) | Fees paid | Renewal fee | 30.09.2009 | Renewal fee patent year 03 | 30.09.2010 | Renewal fee patent year 04 | 08.09.2011 | Renewal fee patent year 05 | 26.09.2012 | Renewal fee patent year 06 | 09.09.2013 | Renewal fee patent year 07 | 08.09.2014 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | CY | 17.06.2015 | EE | 17.06.2015 | LT | 17.06.2015 | LV | 17.06.2015 | MC | 17.06.2015 | MT | 17.06.2015 | IS | 17.10.2015 | [2017/40] |
| Former [2017/22] | EE | 17.06.2015 | |
| LT | 17.06.2015 | ||
| LV | 17.06.2015 | ||
| MC | 17.06.2015 | ||
| MT | 17.06.2015 | ||
| IS | 17.10.2015 | ||
| Former [2016/23] | EE | 17.06.2015 | |
| LT | 17.06.2015 | ||
| LV | 17.06.2015 | ||
| MC | 17.06.2015 | ||
| IS | 17.10.2015 | ||
| Former [2016/10] | EE | 17.06.2015 | |
| LT | 17.06.2015 | ||
| LV | 17.06.2015 | ||
| IS | 17.10.2015 | ||
| Former [2016/09] | EE | 17.06.2015 | |
| LT | 17.06.2015 | ||
| LV | 17.06.2015 | ||
| Former [2015/49] | LT | 17.06.2015 | |
| LV | 17.06.2015 | Cited in | International search | [YX]WO0183503 (HYBRIDON INC [US]) [Y] 1-94 * pages 9,10; figures 1B-3,1B-4; claims 1,3,4 * * figure 1B-3 * [X] 1-5,7,10,11,22-25,27,28,32-34,40-42,66,67,76-94; | [X]WO2005030259 (COLEY PHARM GROUP INC [US], et al) [X] 1-14,20-25,28,32-34,37,39-42,46,48,49,52,59-62,64,66,67,69,70,75-94 * table 1 *; | [X] - TSAO ET AL, "Optically detected magnetic resonance study of the interaction of an arsenic(III) derivative of cacodylic acid with EcoRI methyltransferase Optically detected magnetic resonance study of the interaction of an arsenic(III) derivative of cacodylic acid with EcoRI methyltransferase", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, (19910101), vol. 30, no. 18, ISSN 0006-2960, pages 4565 - 4572, XP002357069 [X] 1-4,10-13,17,22-25,27,28,32-34,40,41,44,46,49,61,66,67 * abstract * DOI: http://dx.doi.org/10.1021/bi00232a029 | [Y] - AGRAWAL SUDHIR ET AL, "Medicinal chemistry and therapeutic potential of CpG DNA", TRENDS IN MOLECULAR MEDICINE, ELSEVIER CURRENT TRENDS, (20020301), vol. 8, no. 3, ISSN 1471-4914, pages 114 - 121, XP009073678 [Y] 1-94 * page 117 * DOI: http://dx.doi.org/10.1016/S1471-4914(01)02264-X | [Y] - EUGEN ULHMANN ET AL, "Recent advances in the development of immunostimulatory oligonucleotides", CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT, CURRENT DRUGS, LONDON, GB, (20030101), vol. 6, no. 2, ISSN 1367-6733, pages 204 - 217, XP009103505 [Y] 1-94 * page 208 * | [Y] - R. P. IYER, ET AL., "Modified Oligonucleotides - Synthesis, Properties and Applications", CURRENT OPINION IN MOLECULAR THERAPEUTICS, (1999), vol. 1, no. 3, pages 344 - 358, XP009103623 [Y] 1-94 * page 352 - page 354 * |